If you own or run a small aesthetic clinic, you have probably asked the same question as many other practitioners: Where do I even start with AI?
That question sat at the heart of Hamilton Fraser’s recent webinar with Ashley McKenna, co-founder and director of EQUALS3. His message to clinic owners was clear: you are not too late, but the window for learning how to use AI safely and commercially is closing.
This does not mean rushing into a three-year contract with the first AI vendor in your inbox. In fact, Ashley’s view is the opposite. Fear of missing out is one of the worst reasons to buy AI software. The better question is not simply whether to adopt AI, but where, when and at what cost.
For aesthetic clinic owners, particularly single-site and small group operators, AI can be useful. It can reduce admin, support marketing workflows, help with note summaries and improve follow-up processes. But it can also create risk if it touches patient data, clinical judgement or consent processes without clear governance.
This guide brings together key insights and frameworks shared by EQUALS3 during the webinar, including:
Hamilton Fraser hosted the session as part of its education-led support for the aesthetics sector. The frameworks, examples and commercial modelling referenced in this article are drawn from EQUALS3’s work and Ashley McKenna’s webinar insights.
Before looking at tools, Ashley encouraged clinic owners to understand the gap between AI use and AI governance.
Generative AI tools such as ChatGPT, Claude and Gemini are no longer niche. Many patients have used them. Your team may already be using them. Some enquiries arriving in your inbox may already have been drafted by AI.
That matters because AI may already be present in your clinic, even if you have not formally adopted it.
According to the figures referenced by EQUALS3, only a minority of micro-businesses have adopted AI in a meaningful way. For small aesthetic clinics, that is understandable. Most do not have large software budgets, dedicated operations teams or spare time to test dozens of tools.
But it also creates an opportunity. Ashley’s view is that early value is often found in practical, low-risk tasks: admin, meeting summaries, data extraction, reminders, internal drafting and lapsed patient reactivation. These are not the most exciting uses of AI, but they can be the most useful.
Ashley highlighted a significant governance gap: many clinics may be using AI in marketing, admin or consultation-adjacent processes without a written AI use policy, updated consent wording or a clear process for informing their indemnifier where relevant.
That is where the risk lives.
If a team member pastes patient information or images into a free consumer AI tool, the issue is not just operational. It could become a data protection, consent, professional standards or indemnity concern.
Many AI pitches sound impressive. Some are useful. Others are ahead of what most small clinics can safely or reliably implement.
Ashley’s advice was to separate the sales promise from what actually ships.
What is often sold: a tool that can conduct or prepare a consultation before the patient attends clinic.
What often ships: a triage form with a large language model layer on top.
This may help collect information, but it is not a clinical consultation. It should not assess suitability, replace practitioner judgement or make clinical decisions. In aesthetics, the consultation is not just data collection. It is where you assess risk, understand motivation, read emotional cues and decide whether treatment is appropriate.
What is often sold: AI that plans, creates, publishes and optimises your marketing with little human input.
What often ships: generic captions, templated emails and higher content volume.
AI can support marketing, but more content does not always mean better content. Clinic marketing needs your tone of voice, compliant claims, clear boundaries and human review. If the AI does not understand your brand, treatments, patient base and regulatory context, it can quickly produce content that feels generic or risky.
What is often sold: a fully automated reception function.
What often ships: a voicemail capture tool, chatbot or basic enquiry triage system.
These tools can be useful when they capture missed enquiries or help route common questions. But they are unlikely to replace the judgement, reassurance and warmth of a trained front-of-house team member. For small clinics, the better aim may be support, not replacement.
What is often sold: instant insight into which patients are likely to lapse.
What often ships: a statistical model that depends heavily on data quality, context and setup.
Predictive tools can be useful, but only if your data is clean and your workflows are clear. A model cannot fix a poor process by itself. As Ashley explained, AI can accelerate what already exists. If the underlying system is weak, it may accelerate the wrong thing.
EQUALS3 uses a simple adoption map when advising clinic clients. It considers two questions:
Category
What it means
Examples
Practical guidance
Adopt now
High capability and clear value
Voice transcription, note summaries, data extraction, drafting from templates
Start here, especially for admin and structured workflows
Handle with care
Promising but higher risk or complexity
Patient chatbots, autonomous marketing campaigns, complex Q&A tools
Use only with clear guardrails, testing and human review
Nice to have
Capable but not always revenue-moving
Meeting minutes, simple email drafting, social image ideas
Helpful if it saves time, but avoid overinvestment
Not ready
Too risky for routine clinic use
Clinical judgement, treatment recommendations, emotional patient conversations
Avoid. Keep these under human clinical control
Ashley described the “Adopt now” category as the place where the early gains often live. These are the “boring wins”: transcription, summarisation, data extraction and template-based drafting.
They are not flashy, but they can save time and build confidence.
If you are exploring how to use AI in aesthetic practice, start with low-risk admin.
Examples include:
The key point is that these tasks should not involve patient-identifiable data. This gives you and your team time to learn how AI behaves, how prompts work, and where outputs need checking.
Ashley’s recommendation was to start small and build judgement through use. The clinics that benefit are not necessarily the ones that buy the most software. They are the ones that learn how to use the tools well.
The next category includes tools that may help commercially but need stronger controls.
These include:
These can support efficiency, but they should not run unchecked. A chatbot, for example, may answer common questions well until it is asked something outside its safe scope. A marketing automation tool may create content quickly, but that content still needs to be accurate, appropriate and consistent with your clinic’s standards.
For patient-adjacent use, the rule is simple: AI can draft, but a human must approve.
Ashley was clear that some areas are not ready for routine AI use in aesthetic practice.
AI should not:
AI can sound confident, but confidence is not the same as clinical accountability. If something goes wrong, the AI tool is not the one answering the complaint. The practitioner is.
One of the most useful parts of the webinar was Ashley’s framing of inaction. Waiting may feel safe, but it is not always cost-free.
Using an illustrative two-room clinic with annual turnover of around £420,000–£460,000, EQUALS3 modelled potential annual leakage of around £38,000 across several areas. This figure is not a guarantee or a Hamilton Fraser claim. It is an example used by EQUALS3 to show how hidden inefficiency can add up.
Potential leakage included:
The point is not to panic. It is to make the hidden cost of inefficient processes visible.
EQUALS3 recommends starting outside the clinical environment and working inwards. Ashley described this as starting with the lowest risk and earning your way back towards more sensitive areas.
This is the safest starting point.
Examples include:
This layer should not use patient-identifiable data. The main risk is usually wasted time, not patient harm or regulatory exposure. It allows you to learn how AI works before moving closer to patient-facing processes.
This is patient-adjacent, so it requires more care.
Examples include:
At this stage, AI may help improve commercial performance. But every patient-facing output should be reviewed by a human before it is sent.
This is where “human in the loop” becomes essential. AI drafts. You decide.
This is the highest-care area.
Examples include AI scribes such as Heidi or Tali, which can listen to consultations and draft notes for practitioner review. Ashley noted that these tools can support a more present consultation experience because the practitioner is not constantly typing or writing.
However, this layer should only be considered once the basics are in place:
An AI scribe can help structure notes. It must not replace the practitioner’s responsibility for those notes.
For guidance on professional protection and cover, clinic owners can review Hamilton Fraser’s relevant indemnity information: Insurance policy must-haves for aesthetic clinics.
Ashley set out clear red lines for clinic owners. These should be reflected in your AI use policy, staff training and consent processes.
Assessment is a clinical responsibility. AI should not decide whether a patient is suitable for treatment.
Treatment planning must remain with the practitioner. If a tool suggests a treatment, that suggestion must not be copied into a plan without professional judgement.
If an AI scribe produces notes, the practitioner must read, correct and approve them. If an error remains in the signed record, responsibility sits with the practitioner.
Patient-identifiable information should not be entered into general consumer AI tools that are not appropriate for clinical data. Clinics should check data processing, storage and GDPR considerations before using any AI system with patient information.
Patient images can be identifiable. They should be treated with the same care as clinical records. Uploading them into general-purpose AI tools may create consent, privacy and data protection risks.
If AI touches consultation records, note-taking or other patient-related workflows, consent wording should be clear. Consent cannot simply be retrofitted after a complaint or concern arises.
For related information, clinic owners may also want to review guidance on GDPR in aesthetics and confidentiality and data protection.
According to Ashley, autonomous or “agentic” marketing is one of the most overhyped areas for clinic owners.
The pitch is attractive: give AI a monthly budget and ask it to plan campaigns, create visuals, schedule posts, monitor analytics and optimise performance automatically.
For most small aesthetic clinics, this is not yet a safe hands-off solution. The risks include:
AI can absolutely support marketing. It can help you brainstorm, draft, segment and test. But it should not be allowed to run your clinic’s reputation without oversight.
Your brand is built on trust. Keep a human in control.
Ashley’s suggested approach was deliberately simple: one tool, one problem, one measured outcome.
Focus on getting your house in order.
This phase is about learning safely. It should not require a complex software stack.
Focus on one commercial leak.
Choose one issue, such as:
Then:
Do not introduce five tools at once. If performance changes, you need to know what caused it.
Focus on what worked.
This is the earliest point to consider moving towards clinical-adjacent tools. Even then, proceed carefully.
Responsible AI adoption in aesthetic clinics is not dramatic. It is documented, measured and controlled.
A well-prepared clinic should be able to say:
This is the difference between casual AI use and responsible AI adoption.
AI is not a silver bullet for aesthetic clinics. It will not replace clinical judgement, patient trust or professional accountability.
But used carefully, it can reduce admin, support follow-up, improve internal workflows and help clinic owners recover time that is currently leaking from the week.
The EQUALS3 message is practical: start with low-risk admin, build your policy, protect patient data, update consent where needed, involve your indemnifier where relevant and only expand when you have evidence that the tool is helping.
If you would like to keep learning, explore Hamilton Fraser’s Content Hub.
You can also review EQUALS3’s free diagnostic tools, including its hidden profit finder, practice friction scorecard and patient reactivation audit, to identify where AI may create the most value in your clinic.
